Zydus Lifesciences Limited announced on Wednesday the approval of its Indocyanine Green generic application, expanding its portfolio of ophthalmic diagnostic agents. This regulatory win is poised to enhance the company's market position in the wound care diagnostic space as it captures the anticipated revenue from this alternative source.